

Press Release



ASKA Pharmaceutical Files an Application for Manufacturing and Marketing Approval for LF111 in Japan

TOKYO, June 24, 2024 – ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi, hereinafter referred to as “ASKA”), a subsidiary of ASKA Pharmaceutical Holdings Co., Ltd. (TSE:4886), announced that ASKA has filed an application for manufacturing and marketing approval for LF111 (generic name: drospirenone) in Japan today.

In January 2020, ASKA acquired exclusive rights to develop and market the Product for the territories of Japan and the Republic of Korea from Insud Pharma (Head Office: Madrid, Spain).

In the Phase III clinical trial conducted for Japanese women seeking contraception, the Product achieved the overall pearl index, which was the primary endpoint of the Trial, thus verifying its efficacy. Subsequently, ASKA filed the application for manufacturing and marketing approval.

ASKA expects that this drug will provide a new option for women who wish to use contraception and contribute to the improvement of their quality of life (QOL).

About LF111

Currently, the Combined Oral Contraceptive Pill (COCP), which contains two types of female hormones, synthetic estrogen and progestin, is used as an oral contraceptive in Japan. This drug, a progestogen-only pill (POP) containing drospirenone, is approved and marketed in 59 foreign countries (as of November 12, 2023). According to the World Health Organization guidelines, POP carries a lower risk of venous thromboembolism than COCP and is more highly recommended than COCP for smokers, obese women, women with hypertension or valvular disease, or those with a history of deep vein thrombosis or pulmonary embolism.

About Insud Pharma

Insud Pharma (<https://www.insudpharma.com/en/>) is a leading Spanish company with a track record in the pharmaceutical and healthcare industry spanning over 45 years. With 9,000 employees worldwide, Insud Pharma’s contribution to global public health is enormous, thanks to the medicines and APIs developed and manufactured at its three highly synergistic business units: industrial (Chemo), brand (Exeltis) and biotechnology (mAbxience).

About the Pearl index

Number of pregnancies per 100 women using the contraceptive method for 1 year (13 cycles) (vs. 100 woman-years)

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.

Corporate Planning Department

Tel: +81-3-5484-8366

Email: kouhou@aska-pharma.co.jp